



## PHARMACY POLICY STATEMENT

### HAP CareSource™ Marketplace

|              |                              |
|--------------|------------------------------|
| DRUG NAME    | Somavert (pegvisomant)       |
| BENEFIT TYPE | Pharmacy                     |
| STATUS       | Prior Authorization Required |

Somavert, approved in 2003, is a growth hormone receptor antagonist indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-I (IGF-I) levels. Somavert binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH, and thus interferes with GH signal transduction. Inhibition of GH action results in decreased serum concentrations of IGF-I, as well as other GH-responsive serum proteins.

Acromegaly is typically the result of a GH-secreting pituitary adenoma, thus surgical resection is the preferred treatment whenever possible as the best chance for a cure. If disease persists after surgery, a first-generation long-acting somatostatin receptor ligand such as octreotide is recommended as first-line therapy. Somavert does not target the tumor.

Somavert (pegvisomant) will be considered for coverage when the following criteria are met:

#### Acromegaly

For **initial** authorization:

1. Member is 18 years old or older; AND
2. Medication must be prescribed by or in consultation with an endocrinologist; AND
3. Member has documented diagnosis of uncontrolled acromegaly confirmed by insulin-like growth factor (IGF-1) elevation above normal; AND
4. Documentation of an inadequate response to surgery or radiation, or they are not an option for the member; AND
5. Member has persistent IGF-1 elevation after optimized treatment with octreotide or lanreotide (**NOTE:** Somavert may be used in combination with octreotide or lanreotide); AND
6. Member has had baseline liver function testing.
7. **Dosage allowed/Quantity limit:** initial dose of 40 mg subcutaneously. Titrate to normalize IGF-1 with a dosage range of 10 mg to 30 mg subcutaneously once daily. Quantity limit: 30 vials per 30 days.

***If all the above requirements are met, the medication will be approved for 6 months.***



For **reauthorization**:

1. Chart notes must show normalized or improved (decreased) IGF-1.

***If all the above requirements are met, the medication will be approved for an additional 12 months.***

**HAP CareSource considers Somavert (pegvisomant) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.**

| DATE       | ACTION/DESCRIPTION  |
|------------|---|
| 11/02/2020 | New policy for Somavert created.  |
| 03/31/2022 | Transferred to new template. Updated references.  |
| 03/19/2025 | Updated references; increased initial authorization length to 6 months; removed three-month trial length; removed note about cabergoline. |

References:

1. Somavert [package insert]. NY, NY: Pharmacia and Upjohn Company LLC; 2023.
2. Katznelson L, Laws ER, Melmed S, et al. Acromegaly: An Endocrine Society Clinical Practice Guideline. *The Journal of Clinical Endocrinology & Metabolism*. 2014;99(11):3933-3951. doi:10.1210/jc.2014-2700
3. Melmed S, Bronstein MD, Chanson P, et al. A Consensus Statement on acromegaly therapeutic outcomes. *Nature Reviews Endocrinology*. 2018;14(9):552-561. doi:10.1038/s41574-018-0058-5
4. Zahr R, Fleseriu M. Updates in Diagnosis and Treatment of Acromegaly. *Eur Endocrinol*. 2018;14(2):57-61. doi:10.17925/EE.2018.14.2.57
5. Fleseriu M, Biller BMK, Freda PU, et al. A Pituitary Society update to acromegaly management guidelines. *Pituitary*. 2021;24(1):1-13. doi:10.1007/s11102-020-01091-7

Effective date: 10/01/2025

Revised date: 03/19/2025